Observational studyArchives of gynecology and obstetrics2025
Attitudes towards ferric derisomaltose among Swiss patients with iron deficiency and their treating physicians: the prospective, observational Real-CHOICE study.
Observational study in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04318405 (Iron Isomaltoside 1000 in Patients With Iron Deficiency or Iron Deficiency Anemia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Iron Isomaltoside 1000 in Patients With Iron Deficiency or Iron Deficiency Anemia: a Multicentric, Prospective, Longitudinal, Observational Study in Switzerland.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIron deficiency (ID) often leads to iron deficiency anemia (IDA). Oral iron supplements are frequently associated with gastrointestinal intolerance and poor adherence. Ferric derisomaltose (FDI), a single high-dose intravenous (IV) infusion, is another option. The real-world Real-CHOICE study investigated the attitudes of patients with IDA and ID without anemia (IDNA) towards IV iron therapy. Secondary objectives were the effectiveness and safety of FDI.
methodsReal-CHOICE (NCT04318405) enrolled adults with IDA or IDNA in Switzerland. Custom questionnaires evaluated attitudes and treatment satisfaction at baseline and follow-up (≥ 12 weeks). Hemoglobin, ferritin, and transferrin saturation levels, and treatment-emergent adverse events (TEAEs) were assessed.
resultsOf 319 patients (114 with IDA, 205 with IDNA) who received FDI, most were female (n = 305, 93.9%) and aged < 65 years (n = 298, 91.7%). Over three-quarters of patients were not hesitant to receive IV iron treatment at baseline (n = 228, 76.3%) and follow-up (n = 194, 78.2%). The proportion of patients whose attitude towards receiving IV iron therapy remained stable or improved at follow-up versus baseline was 86.1% (n = 204/237). Of 195 patients with available data, mean (standard deviation) changes from baseline to follow-up in hemoglobin, ferritin, and transferrin saturation levels were 1.15 (1.50) g/dL, 144.87 (131.77) µg/L, and 8.71% (13.29%), respectively. TEAEs and adverse drug reactions occurred in 76 (23.8%) and 22 patients (6.9%), respectively.
conclusionReal-CHOICE revealed favorable attitudes of patients and physicians towards IV iron therapies, particularly FDI, in a real-world setting. Improved hematologic parameters and favorable safety highlight FDI's potential as a clinically effective treatment for ID and IDA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.